Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck

Cancer

Volumn 97, Issue 7, 2003, Pages 1701-1710

  McLaughlin, Patricia J ^a   Stack Jr , Brendan C ^a   Levin, Roger J ^a   Fedok, Fred ^a   Zagon, Ian S ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Epithelial cells; Inhibitory growth factor; Opioid growth factor (OGF); Opioid growth factor receptor (OGFr); Squamous cell carcinoma of the head and neck (SSCHN)

Indexed keywords

GROWTH FACTOR RECEPTOR; METENKEPHALIN; OPIATE PEPTIDE; OPIOID GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL PROLIFERATION; CHILD; DISEASE MARKER; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GROWTH INHIBITION; GROWTH REGULATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; RNA BINDING; RNA TRANSLATION; SQUAMOUS CELL CARCINOMA; TONSILLECTOMY; TUMOR GROWTH; UVULOPALATOPHARYNGOPLASTY; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; RECEPTORS, OPIOID;

EID: 0037377757     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11237     Document Type: Article

References (30)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64.
3. Carew JF, Shah JP. Advances in multimodality therapy for laryngeal cancer. CA Cancer J Clin. 1998;48:211-228.
4. Vikram B. Adjuvant therapy in head and neck cancer. CA Cancer J Clin. 1998;48:199-209.
5. Lango MN, Dyer KF, Lui VW, et al. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2002;94:375-383.
6. Leong PL, Xi S, Drenning SD, et al. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene. 2002;21:2846-2853.
7. van Gog FB, Brakenhoff RH, Stigter-van Wlasum M, Snow GB, Van Dongen GA. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int J Cancer. 1998;77:13-18.
8. McLaughlin PJ, Levin RJ, Zagon IS. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol. 1999;14:991-998.
9. McLaughlin PJ, Levin RJ, Zagon IS. The opioid growth factor receptor in human head and neck squamous cell carcinoma. Int J Mol Med. 2000;5:191-196.
10. 5]-enkephalin, and the zeta opioid receptor in head and neck squamous cell carcinoma. Laryngoscope. 1997;107:335-339.
11. Zagon IS, Roesener CD, Verderame MF, Ohlsson-Wilhelm BM, Levin RJ, McLaughlin PJ. Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol. 2000;17:1053-1061.
12. Zagon IS, Wu Y, McLaughlin PJ. Opioid antagonist modulation of DNA synthesis in mouse tongue epithelium is circadian dependent. Pharmacol Biochem Behav. 1994;48:709-714.
13. Zagon IS, Wu Y, McLaughlin PJ. Opioid growth factor inhibits DNA synthesis in mouse tongue epithelium in a circadian rhythm-dependent manner. Am J Physiol. 1994;267:R645-R652.
14. Zagon IS, Sassani JW, Kane ER, McLaughlin PJ. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor. Brain Res. 1997;759:92-102.
15. Zagon IS, Sassani JW, McLaughlin PJ. Re-epithelialization of the rabbit cornea is regulated by opioid growth factor. Brain Res. 1998;803:61-68.
16. Zagon IS, Wu Y, McLaughlin PJ. Opioid growth factor is present in human and mouse gastrointestinal tract and tonically inhibits DNA synthesis. Am J Physiol. 1997;272:R1094-1104.
17. Zagon IS, Wu Y, McLaughlin PJ. Opioid growth factor and organ development in rat and human embryos. Brain Res. 1999;839:313-322.
18. 5]-enkephalin, inhibits DNA synthesis during recornification of mouse tail skin. Cell Prolif. 2000;33:63-73.
19. Levin RJ, McLaughlin PJ. Growth inhibition by opioid growth factor of human squamous cell carcinoma transplanted into nude mice [abstract]. FASEB J. 1999;13;A192.
20. 5]-enkephalin, in ocular surface epithelium. Brain Res. 1998;792:72-78.
21. Pikula KL, Harris EF, Desiderio DM, Fridland GH, Lovelace JL. Methionine enkephalin-like, substance P-like, and β-endorphin-like immunoreactivity in human parotid saliva. Arch Oral Biol. 1992;37:705-709.
22. Tepperman FS, Jarvis A, Hirst M. Detection of enkephalin-like immunoreactive material in human saliva. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:285-289.
23. 5]-enkephalin. Brain Res. 1999;849:147-154.
24. Zagon IS, Verderame MF, Zimmer WE, McLaughlin PJ. Molecular characterization and distribution of the opioid growth factor receptor (OGFr) in mouse. Mol Brain Res. 2000;84:106-114.
25. Zagon IS, Verderame MF, Allen SS, McLaughlin PJ. Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans. Brain Res. 2000;856:75-83.
26. 5]-enkephalin levels in the developing rat heart. Mol Brain Res. 1998;60:160-167.
27. McLaughlin PJ, Yu Y. Identification and characterization of the ζ-opioid receptor in developing rat heart. Am J Physiol. 1997;272:R1841-R1846.
28. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev. 2002;38:351-376.
29. Looser KG, Shah JP, Strong EW. The significance of "positive" margins in surgically resected epidermoid carcinoma. Head Neck Surg. 1978;1:107-111.
30. Lee JG. Detection of residual carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: a study of surgical margins. Trans Am Acad Ophthalmol Otolaryngol. 1974;78:49-53.